Share this article on:

Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results

Kjeldsen, Sverre E.a; Sica, Domenicb; Haller, Hermannc; Cha, Gloriad; Gil-Extremera, Blase; Harvey, Peterf; Heyvaert, Frankg; Lewin, Andrew J.h; Villa, Giuseppei; Mancia, Giuseppej; for the DISTINCT Investigators

doi: 10.1097/HJH.0000000000000331
ORIGINAL PAPERS: Therapeutic aspects

Objectives: DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS – Candesartan Therapy) aimed to determine the dose–response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension.

Methods: In this 8-week, multinational, multicentre, randomized, double-blind, placebo-controlled study, adults with mean seated DBP of at least 95 to less than 110 mmHg received combination or monotherapy with nifedipine GITS (N) 20, 30 or 60 mg and candesartan cilexetil (C) 4, 8, 16 or 32 mg, or placebo. The primary endpoint, change in DBP from baseline to Week 8, was analysed using the response surface model (RSM); this analysis was repeated for mean seated SBP.

Results: Overall, 1381 participants (mean baseline SBP/DBP: 156.5/99.6 mmHg) were randomized. Both N and C contributed independently to SBP/DBP reductions [P < 0.0001 (RSM)]. A positive dose–response was observed, with all combinations providing statistically better blood pressure (BP) reductions from baseline versus respective monotherapies (P < 0.05) and N60C32 achieving the greatest reduction [–23.8/–16.5 mmHg; P < 0.01 versus placebo (–5.3/–6.7 mmHg) and component monotherapies]. Even very low-dose (N20 and C4) therapy provided significant BP-lowering, and combination therapy was similarly effective in different racial groups. N/C combination demonstrated a lower incidence of vasodilatory adverse events than N monotherapy (18.3 versus 23.6%), including headache (5.5 versus 11.0%; P = 0.003, chi-square test) and peripheral oedema over time (3.6 versus 5.8%; n.s.).

Conclusion: N/C combination was effective in participants with hypertension and showed an improved side effect profile compared with N monotherapy.

aOslo University Hospital Ullevaal, University of Oslo, Oslo, Norway

bVirginia Commonwealth University, Richmond, Virginia, USA

cHannover Medical School, Hannover, Germany

dKRK Medical Research Institute, Dallas, Texas, USA

eHospital Universitario San Cecilio, Granada, Spain

fThe Crouch Oak Family Practice, Surrey, UK

gHuisartsenpraktijk De Regenboog, Antwerp, Belgium

hNational Research Institute, Los Angeles, California, USA

iFondazione S. Maugeri - IRCCS, Pavia

jUniversity of Milano-Bicocca, Milan, Italy

Correspondence to Professor Sverre E. Kjeldsen, MD, PhD, Department of Cardiology, Ullevaal Hospital, N-0407 Oslo, Norway. Tel: +47 22119100; fax: +47 22119181.

Abbreviations: ACE, angiotensin-converting enzyme; ANCOVA, analysis of covariance; ARB, angiotensin receptor blocker; C, candesartan cilexetil; CCB, calcium channel blocker; DISTINCT, reDefining Intervention with Studies Testing Innovative Nifedipine GITS – Candesartan Therapy; FDC, fixed-dose combination; GCP, good clinical practice; GFR, glomerular filtration rate; GITS, gastrointestinal therapeutic system; ICH, International Conference on Harmonization; IEC, independent ethics committee; IRB, institutional review board; LOCF, last observation carried forward; MedDRA, Medical Dictionary for Regulatory Activities; N, nifedipine GITS; RSM, response surface model; TEAE, treatment-emergent adverse event

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

Received March 7, 2014

Received in revised form July 7, 2014

Accepted July 8, 2014

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins